Key takeaways
- “Peptide” is a structural word: it covers hormones your body makes, approved prescription medicines and research compounds approved nowhere.
- Approved peptide medicines such as semaglutide have known side effects, measured in large trials and printed on the label.
- In a July 2026 briefing for its advisory committee, FDA staff concluded there is insufficient clinical safety information to characterise the safety profile of BPC-157. The FDA’s compounding safety-risk page says it has not identified any human exposure data for TB-500.
- Between them, regulators in the US, UK and Australia point to four practical risks: not knowing what is in the vial, immune reactions, unknown long-term effects and use without medical supervision.
- A small study with no reported problems cannot show that something is safe. It can only rule out problems that are common.
01Does being a peptide make something safe?
A peptide is a short chain of amino acids. That tells you how a molecule is built, not what it does or how risky it is.
Your body makes peptides: oxytocin is 9 amino acids long, glucagon 29. Some peptides are approved prescription medicines, such as semaglutide and tirzepatide. Some are cosmetic ingredients. Others, such as BPC-157 and TB-500, are research compounds not approved as medicines anywhere. Asking whether “peptides” are safe is like asking whether “pills” are safe. The answer depends on the molecule, the product, the standard it was made to, and how well it has been studied in people.
For the basics, start with what are peptides and types of peptides.
02Which peptides have safety data?
Approved peptide medicines have safety data from controlled trials and a label listing known risks. Most research peptides have little or no controlled human safety data.
| Kind | Example | What is known about safety in people | Where that comes from |
|---|---|---|---|
| Approved medicine | Semaglutide, tirzepatide (prescription medicines) | Side effects were measured in large controlled trials and are listed on the label. The US label for Wegovy (semaglutide) carries a boxed warning: it causes thyroid C-cell tumours in rodents, and whether it does so in humans is unknown. It also lists warnings including acute pancreatitis and gallbladder disease. | Phase 3 trials (STEP 1, 68 weeks; SURMOUNT-1, 72 weeks) and the FDA-approved labels (Wegovy, revised June 2026; Zepbound, revised August 2026) |
| Investigational drug | Retatrutide (investigational; not approved anywhere) | Adverse events were measured in controlled trials of the developer’s product, which no regulator has approved. In the phase 2 trial the most common adverse events were gastrointestinal and dose-related, and heart rate rose, peaking at 24 weeks. | Phase 2 randomised trial, n=338, 48 weeks (NEJM, 2023) |
| Unapproved research compound | BPC-157, TB-500, injectable GHK-Cu | Little or no controlled human safety data. FDA staff, July 2026 briefing, on BPC-157: “There is insufficient clinical safety information to characterize the safety profile.” On TB-500, FDA “has not identified any human exposure data.” On injectable GHK-Cu: possible immune reactions from aggregation and peptide-related impurities, and “limited data in humans.” | FDA advisory committee briefing (July 2026) and FDA compounding safety-risk page (current as of 22 April 2026) |
The grades behind “what is known” are explained in evidence grades.
03What risks do regulators name for unapproved peptide products?
Between them, regulators in the US, UK and Australia point to four practical risks with unapproved peptide products: unknown contents, immune reactions, unknown long-term effects and use without medical supervision.
“The biggest risks with unapproved peptide products are not knowing what is in the vial,” the TGA’s chief medical adviser said in September 2026, after a product sold as retatrutide was found to contain semaglutide and no retatrutide. The UK MHRA said in October 2026 that seized products “have not been assessed for safety, quality or effectiveness.” Victoria’s Chief Health Officer said the substance, concentration and possible contaminants in these products are unknown. Details: contamination and mislabeling.
The FDA notes that peptides can provoke immune responses, with consequences that “may range from antibody responses with no apparent clinical manifestations to life-threatening and catastrophic reactions.” It says impurities and clumped peptide (aggregates) can raise that risk, and that subcutaneous and nasal routes carry more risk than oral or rectal ones. Victoria recorded 13 cases of anaphylaxis linked to unapproved peptides between July 2025 and October 2026; the advisory did not attribute them to a specific substance.
The published human studies of BPC-157 are, in FDA staff’s words, “of short duration” with “small sample sizes.” A 2026 narrative review in the Journal of the American Academy of Orthopaedic Surgeons concluded that validated pharmacokinetic and long-term safety data for BPC-157 are lacking.
A 2026 case report described a woman in her mid-20s admitted to hospital with persistent nausea and vomiting after a series of injections of an unverified product reported to contain retatrutide, given in a wellness setting by someone without medical qualifications. She had not considered the injections to be medication; they came to light only after repeated questioning. The MHRA says anyone considering GLP-1 treatment should speak to a healthcare professional; Victoria advises discussing any use of unapproved peptides with a GP.
04Does “no side effects reported” mean a peptide is safe?
No. A small study with no reported problems cannot show that something is safe. Small studies can miss uncommon harms. A long-standing statistical rule, the “rule of three” (Hanley and Lippman-Hand, 1983), says that if nothing goes wrong in n people, the true rate of that problem could still be as high as about 3 ÷ n, at the usual 95% level of confidence. The shortcut is for larger groups; for very small ones the table gives the exact figure.
| People studied, no problems seen | The problem could still affect up to… |
|---|---|
2 | About 3 in 4 people (the exact figure; 3 ÷ n does not work for groups this small) |
20 | About 1 in 7 people |
300 | About 1 in 100 people |
3,000 | About 1 in 1,000 people |
That is why FDA staff, reviewing five small human studies of BPC-157, wrote that no serious adverse events “appear to have been reported” and, in the same paragraph, that the studies were short, small and gave “limited information on safety data.” Both halves matter.
05What we don't know
- Long-term effects of any unapproved research peptide in people. We found no published long-term human study of BPC-157, TB-500 or injectable GHK-Cu (PubMed, November 2026).
- How often harm occurs. Reporting is voluntary and incomplete. The FDA notes that compounding pharmacies under section 503A generally do not report adverse events to it, and people using research products may not tell their doctors.
- Effects in specific groups, such as people with medical conditions, during pregnancy, or alongside other medicines. The small human studies were not designed to answer these questions.
- Whether a clean vial changes the answer. A full lab report shows what was in the tested sample from that batch. It does not create safety data for the molecule.
Had a reaction to any product? Seek medical care first. Victoria’s Chief Health Officer put it plainly: people “should not delay seeking care because of concerns about how or where the product was obtained.” Then report it: FDA MedWatch (US), MHRA Yellow Card (UK) or the TGA (Australia).
Plain-English summary of public sources, checked 18 November 2026. Not medical or legal advice. For anything about your health, a doctor who knows you is the right call.
This content is educational. It is not medical advice and does not describe use in humans. 6AM Wellness products are sold for research use only and are not for human consumption. If you have a health condition, consult a licensed clinician who knows you.